000			03433nam a2200361 c 4500
999			_c81558 _d81558
001			81558
003			ES-MaUEC
005			20230213143659.0
008			141127s2015 gw | s |||| 0|eng d
020			_a9783662450246
040			_aES-MaUEC
050		4	_aQR189 _b.V333 2015 EB
082	0	4	_a615.372
245	0	0	_aVaccine Analysis : _bStrategies, Principles, and Control _cedited by Brian K. Nunnally, Vincent E. Turula, Robert D. Sitrin
260			_aBerlin, Heidelberg _bSpringer _c2015
300			_a1 recurso en línea (XII, 665 p.) _b124 il.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aLive Attenuated Viral Vaccines -- Inactivated Viral Vaccines -- Recombinant Virus Like Particle Protein Vaccines -- Analysis of influenza vaccines -- Live-attenuated and inactivated whole-cell bacterial vaccines -- Analytical control strategy of bacterial subunit vaccines -- Bacterial Polysaccharide Vaccines: Analytical Perspectives -- Glycoconjugate vaccines -- Vaccines in research and development: new production platforms and new biomolecular entities for new needs -- Role of Analytics In Viral Safety -- Deep Sequencing Applications for Vaccine Development and Safety -- Quality-by-design: As related to analytical concepts, control and qualification -- Vaccine Potency Assays -- Establishing a Shelf-life and Setting Lot-release Specifications -- Vaccine Reference Standards -- Lot Release of Vaccines by Regulatory Authorities and Harmonization of Testing Requirements -- Dendritic cell targeting vaccines.
520			_aThis book is an indispensable tool for anyone involved in the research, development, or manufacture of new or existing vaccines. It describes a wide array of analytical and quality control technologies for the diverse vaccine modalities. Topics covered include the application of both classical and modern bio-analytical tools; procedures to assure safety and control of cross contamination; consistent biological transition of vaccines from the research laboratory to manufacturing scale; whole infectious attenuated organisms, such as live-attenuated and inactivated whole-cell bacterial vaccines and antiviral vaccines using attenuated or inactivated viruses; principles of viral inactivation and the application of these principles to vaccine development; recombinant DNA approaches to produce modern prophylactic vaccines; bacterial subunit, polysaccharide and glycoconjugate vaccines; combination vaccines that contain multiple antigens as well as regulatory requirements and the hurdles of licensure.
650		7	_aVacunas _0comprobar BNE19900984775 _2embne _9140409
700	1		_aNunnally, Brian K. _eeditor literario _994038 _0Local
700	1		_aTurula, Vincent E. _eeditor literario _994039 _0Local
700	1		_aSitrin, Robert D. _eeditor literario _994040 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-662-45024-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783662450246
907			_a.b12901489 _b10-10-17 _c18-01-16
942			_2lcc _cLE
945			_aQR189 .V333 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i1157110x _z06-04-17
988			_aEBOOK, EBSPRINGER
998			_am _a_alco _a_vill _b05-07-17 _cm _dz _ef _feng _ggw _h0